HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo

Spring is here in always-sunny Philadelphia. The vernal equinox has brought us an unexpected bounty of noteworthy news: Cigna’s clever vertical integration move Merck cuts drug prices—and Medicaid and 340B pay more Walgreens’ big pharmacy technology play How plans profit—and patients lose—from highl

By Drug Channels · Mar 31, 2026 · via Drug Channels

This is an aggregated industry headline. Read the full story at Drug Channels

Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Rising Stars: WPP's Meghan O'Hora on the 'complex puzzle' of oncology drug marketing
The WeekFiercePharma ↗
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
Jun 3, 2026
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
The WeekFierceBiotech ↗
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-r…
Jun 3, 2026
Cingulate’s FDA Rejection Centers on Manufacturing, Not Safety
The WeekBriefing
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…
Jun 3, 2026